Phase 1 Metastatic Malignant Solid Neoplasm trials recruiting now

All Metastatic Malignant Solid Neoplasm trials, every phase

Other phases for Metastatic Malignant Solid Neoplasm

Phase 1 Metastatic Malignant Solid Neoplasm trials

• BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
  NCT07594626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
  NCT04119024 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Imaging of Solid Tumors Using 18F-TRX
  NCT06942104 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
  NCT04329494 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
  NCT05098210 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
  NCT05039632 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
  NCT07189195 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
  NCT05803382 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
  NCT05691491 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 23 locations
• Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
  NCT05111561 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
  NCT05372640 · Phase: Phase 1 · Ages: 12 Years and older · Sex: All (male and female) · 7 locations
• Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
  NCT05372614 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
  NCT07137416 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.